Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockBearish
5
Neutral
5
Bullish
4
Bearish
5
Neutral
5
Bullish
36
Bearish
0
Neutral
0
Bullish
32
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Granules India Limited is a vertically integrated pharmaceutical company specializing in Active Pharmaceutical Ingredient (API), Pharmaceutical Formulation Intermediates (PFI), and Finished Dosage (FD). Known for its leadership in off-patent drugs, it serves global branded and generic pharma firms with core products like Paracetamol and Ibuprofen.
In Q3 FY26, Granules India reported a 22% year-over-year revenue growth, driven mainly by the Finished Dosage segment in North America and Europe. Their EBITDA also saw a meaningful jump of 34% year-over-year, signifying improved operating leverage.
The company's strategic expansions include significant market penetration in Europe achieving a 131% year-over-year revenue growth in the region. They hold a leading position in 25% of their US product portfolio and received key GMP certifications, bolstering their regulatory compliance.
Granules India is actively engaged in R&D, noted for their strides in peptide chemistry and controlled substances. They have made advances like the tentative approval of Amphetamine ER in the US market, asserting their innovative pathway.
The management expressed confidence in resolving FDA concerns at their Gagillapur site. Concurrently, they are expanding geographical reach and strategic areas like peptides, complex generics, and sustainability efforts, maintaining robust governance and supply chain resilience.
Pharmaceuticals & Biotechnology
Pharmaceuticals
16,680 Cr
Moderate Risk
29.3
32.3
1.1
3.9
654.85
422.15
Sales CAGR
Profit CAGR
ROE
ROCE
Upcoming Result Date: Apr 28, 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Granules India Ltd (GRANULES) is currently trading at 670.85 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Granules India Limited is a vertically integrated pharmaceutical company specializing in Active Pharmaceutical Ingredient (API), Pharmaceutical Formulation Intermediates (PFI), and Finished Dosage (FD). Known for its leadership in off-patent drugs, it serves global branded and generic pharma firms with core products like Paracetamol and Ibuprofen. In Q3 FY26, Granules India reported a 22% year-over-year revenue growth, driven mainly by the Finished Dosage segment in North America and Europe. Their EBITDA also saw a meaningful jump of 34% year-over-year, signifying improved operating leverage. The company's strategic expansions include significant market penetration in Europe achieving a 131% year-over-year revenue growth in the region. They hold a leading position in 25% of their US product portfolio and received key GMP certifications, bolstering their regulatory compliance. Granules India is actively engaged in R&D, noted for their strides in peptide chemistry and controlled substances. They have made advances like the tentative approval of Amphetamine ER in the US market, asserting their innovative pathway. The management expressed confidence in resolving FDA concerns at their Gagillapur site. Concurrently, they are expanding geographical reach and strategic areas like peptides, complex generics, and sustainability efforts, maintaining robust governance and supply chain resilience.
Over the past 52 weeks, Granules India Ltd has traded between a low of ₹422.15 and a high of ₹654.85. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Granules India Ltd has a market capitalization of approximately 16,680.45. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Granules India Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 29.32 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 16,680.45 Cr, Granules India Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Granules India Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Granules India Ltd is 29.32. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The 10,000 crore Biopharma Shakti initiative supports domestic production of biologics and biosimilars, aligning with Granules India's strategic shift toward complex generics and its peptide CDMO platform.
Granules India's board has approved a plan to raise up to ₹1,762.50 crore. This includes ₹1,462.50 crore from convertible warrants and ₹300 crore from the issuance of equity shares.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Earnings Call
Granules India will host its Q4 and FY2026 earnings conference call on Wednesday, 29 April 2026 at 5:00 PM IST to discuss financial performance and business updates; management and dial-in details provided.
Earnings Call Schedule
Granules India will hold an analyst/investor earnings conference call to discuss Q4 and FY2026 results on April 29, 2026 at 5:00 PM IST; management participation and dial-in/RSVP details provided.
Board Meeting Notice
Granules India has scheduled a Board meeting on 29-Apr-2026 to consider and approve audited Q4 & FY2025-26 financial results and to consider recommendation of a final dividend; insider trading window closed till 01-May-2026.
Board Meeting
Granules India scheduled a Board meeting on April 29, 2026 to consider and approve audited financial results for Q4 and FY ended Mar 31, 2026 and to recommend a final dividend if any; insider trading window closed until May 1, 2026.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1027.85 | 19,183 Cr | 11.82 | 2.22 | 0.56 | 17.79 | 21.15 | 14.81 | ||
1344.50 | 18,721 Cr | 43.21 | 5.33 | 0.53 | 13.45 | 14.38 | 6.57 | ||
1403.95 | 18,464 Cr | 812.30 | 3.13 | 0.00 | 2.34 | 3.64 | 0.25 | ||
645.35 | 16,680 Cr | 29.32 | 3.89 | 0.22 | 12.88 | 13.37 | 7.86 | ||
777.10 | 15,377 Cr | 89.53 | 13.40 | 0.00 | 26.49 | 22.49 | 11.57 | ||
784.95 | 15,021 Cr | 24.54 | 2.82 | 1.44 | 11.93 | 12.59 | 7.45 | ||
841.00 | 14,762 Cr | 30.87 | 2.24 | 0.54 | 7.25 | 7.77 | 3.18 | ||
| Median: 7 Co. | — | 841.00 | 16,680 Cr | 30.87 | 3.13 | 0.53 | 12.88 | 13.37 | 7.45 |
